Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma

Laboratory Hematology

Volumn 12, Issue 1, 2006, Pages 47-54

  Katodritou, Eirini ^a   Speletas, Matthaios ^a   Zervas, Kostas ^a   Kapetanos, Dimitrios ^a   Georgiou, Elisabeth ^a   Christoforidou, Anna ^a   Pavlitou, Aikaterini ^a   Sion, Michael ^a   Christakis, John ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Anemia; Hypochromic erythrocytes; Multiple myeloma; r HuEPO; sTfR F index

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; MELPHALAN; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; TRANSFERRIN RECEPTOR; VINCRISTINE;

ADULT; AGED; ANALYTIC METHOD; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG RESPONSE; ERYTHROCYTE; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; IRON THERAPY; MALE; MULTIPLE MYELOMA; PATIENT CODING; PREDICTION; PROTEIN ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, HYPOCHROMIC; ERYTHROCYTE COUNT; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MULTIPLE MYELOMA;

EID: 33645339549     PISSN: 10802924     EISSN: None     Source Type: Journal    
DOI: 10.1532/LH96.05030     Document Type: Article

References (38)

1. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50:29-40.
2. Beguin Y, Yerna M, Loo M, Weber M, Fillet G. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol. 1992;82: 648-653.
3. Musto P, Falcone A, D'Arena G, et al. Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis. Eur J Haematol. 1997;58:314-319.
4. Beguin Y. Erythropoiesis and erythropoietin in multiple myeloma. Leuk Lymphoma. 1995;18:413-421.
5. Kaushansky K. Multiple myeloma: multiple ways to defeat erythropoiesis. Blood. 2001;97:1153.
6. Means R, Krantz S. Progress in understanding the pathogenesis of anemia of chronic disease. Blood. 1992;80:1639-1647.
7. Thomas C, Thomas L. Biochemical and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem. 2002;48: 1066-1076.
8. Cavill I. Erythropoiesis and iron. Best Pract Res Clin Haematol. 2002;15:399-409.
9. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997;89:1052-1057.
10. Suominen P, Punnonen K, Rajamaki A, Irjala K. Serum transferrin receptor and transferrin receptor-ferritin index identify healthy subjects with sub clinical iron deficits. Blood. 1998;92:2934-2939.
11. Fishbane S, Galgano S, Langley R, Maesaka J. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 1997;52:217-222.
12. Braun J, Lidner K, Schreiber R, Heidler R, Horl W. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v iron supplementation in maintenance hemodialysis patients. Nephrol Dial Transplant. 1997;12:1173-1181.
13. Macdougall I. Merits of percentage hypochromic red cells as a marker of functional iron deficiency. Nephrol Dial Transplant. 1998;13:847-849.
14. Tessitore N, Solero G, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in hemodialysis patients. Nephrol Dial Transplant. 2001;16:1416-1423.
15. Barosi G, Cazzola M, De Vincentiis A, Grossi A, Tura S. Guidelines for the use of recombinant human erythropoietin. Haematologica. 1994;79:526-533.
16. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994;84:1056-1063.
17. Henry D, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin (r-HuEPO/Epoietin a) therapy in cancer patients. Blood. 1995;85:1676-1678.
18. Osterborg A, Boogaerts M, Cimino R, et al. Recombinant human erythropoetin in transfusion dependent anemic patients with multiple myeloma and Non Hodgkin's Lymphoma. A randomized multi-center study. Blood. 1996;87:2675-2682.
19. Cazzola M, Ponchio L, Pedrotti C, et al. Prediction of response to recombinant human erythropoietin (r-huEPO) in anemia of malignancy. Haematologica. 1996;81:434-441.
20. Cazzola M, Beguin Y, Kloczko J, Spicka I, Cioffier B. Once-weekly epoietin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol. 2003;122:386-393.
21. Glaspy J, Cavill I. Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology. 1999; 13:461-473.
22. Katodritou E, Speletas M, Kapetanos D, et al. Prediction of response of anemia to recombinant human erythropoietin in patients with multiple myeloma and lymphoma: evaluation and interim analysis of traditional and novel predictive markers. Hematol J. 2004;5(suppl 2):191.
23. Arndt U, Kaltwasser JP, Gottschalk R, Hoeltzer D, Moller B. Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin. Ann Hematol. 2005;84:159-166.
24. Kooistra M, van Es A, Struyvenberg A. Low iron absorption in erythropoietin-treated hemodialysis patients. J Am Soc Nephrol. 1995;6:543.
25. Eschbach J, Cook J, Scribner B. Iron balance in hemodialysis patients. Ann Intern Med. 1977;87:710-713.
26. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood. 1997;89: 4248-4267.
27. Silverberg DS, Blum M, Agbaria Z, et al. Intravenous iron for the treatment of predialysis anemia. Kidney Int. 1999;69(suppl): S79-S85
28. Brugnara C, Chambers L, Malynn E, Goldberg M, Kruskall M. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. Blood. 1993;81:956-964.
29. Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol. 2005; 11: 14-23.
30. Ludwig H, Rai K, Blade J, et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoietin treatment reccomendations. Hematol J. 2002; 3:121-130.
31. Krause A, Neitz S, Magert H, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480:147-150.
32. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001; 276:7806-7810.
33. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute phase protein. Blood. 2003;101:2461-2463.
34. Auerbach M, Ballard H, Trout R, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open label, randomized trial. J Clin Oncol. 2004;22:1301-1307.
35. Weinberg E. Iron therapy and cancer. Kidney Int. 1999;55: 131-134.
36. Weinberg E. The role of iron in cancer. Eur J Cancer Prev. 1995; 5:19-36.
37. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoietin A in clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997;15:1218-1234.
38. Katodritou E, Speletas M, Zervas K, et al. Novel hematologic markers for predicting response to r-huEPO in anemic patients with multiple myeloma and lymphoma [abstract]. Haematologica/Hematol J. 2005;90(suppl 2):187.